Skip to main content
. 2010 Sep 20;2:151–161. doi: 10.2147/DHPS.S6215

Table 2.

Phosphodiesterase-5 inhibitor pharmacokinetic profile4446

Drug Bioavailability (%) Time to peak onset (hours) Metabolism (metabolite activity) Half-life (hours) Elimination Protein binding (%)
Sildenafil 41 0.5–2 Hepatic (active) 4 Fecal (80%)
Renal (13%)
96
Tadalafil N/A 2–8 Hepatic (inactive) 15 Fecal (61%)
Renal (36%)
94
Vardenafil 15 0.5–2 Hepatic (active) 4–5 Fecal (91%–95%)
Renal (2%–6%)
95

Abbreviation: N/A, not available.